Rolaids Recalled Over Metal Particles in Product

Johnson & Johnson (J&J) corporate headquarters in New Brunswick, N.J. are shown in a file photo from July 19, 2002. Ending a weeklong legal standoff, Johnson & Johnson agrees to acquire the struggling medical device manufacturer Guidant Corp. for $21.5 billion, about 15 percent less than its initial offer last year.
Johnson & Johnson on Thursday recalled several types of Rolaids antacids in the U.S. because of reports of metal and wood particles in the products.

The voluntary recall comes less than a month after the company issued another voluntary recall over a type of Rolaids product.

The products include Rolaids Extra Strength Softchews, Rolaids Extra Strength plus Gas Softchews and Rolaids Multi-Symptom plus Anti-Gas Softchews. The company says the materials were potentially introduced into the products during the manufacturing process at an outside manufacturer.

The New Brunswick, N.J., company which has issued multiple recalls in recent months is suspending production of the Rolaids products in question.

In November, it recalled Children's Benadryl Allergy Fastmelt Tablets, Junior Strength Motrin Caplets, and Extra Strength Rolaids softchews. It issued that recall after reviewing its manufacturing process in the wake of a series of product recalls over the last year. The company said it found unspecified problems related to Benadryl and Motrin products.

The Rolaids softchews were recalled because some consumers complained the Rolaids had an unusual texture that J&J traced to crystallized sugar.

All the products are sold by J&J's McNeil Consumer Healthcare business.

Shares of Johnson & Johnson fell 39 cents to close Thursday $62.02.